Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal doxorubicin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of liposomal doxorubicin and paclitaxel. Liposomal doxorubicin is a formulation where doxorubicin is encapsulated in liposomes to help reduce cardiotoxicity while maintaining anticancer efficacy. Paclitaxel is a taxane that promotes microtubule assembly and stability, preventing cell division. This combination is primarily used in the treatment of metastatic breast cancer and has shown efficacy with relatively low rates of cardiac toxicity compared to conventional doxorubicin combinations.
02
Targets
MicrotubuleDNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on liposomal doxorubicin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal doxorubicin + paclitaxel.